- Report
- April 2025
- 194 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 116 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 183 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 69 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 381 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 266 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 244 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 398 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 78 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 194 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 309 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 100 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 303 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 192 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 183 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 196 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 193 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 474 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 94 Pages
Global
From €5317EUR$5,850USD£4,515GBP
- Report
- April 2025
- 402 Pages
Global
From €5317EUR$5,850USD£4,515GBP

The Antimicrobial Resistance (AMR) market is a subset of the healthcare services industry that focuses on the development of treatments and strategies to combat the growing threat of drug-resistant bacteria. AMR is a major public health concern, as it can lead to increased morbidity and mortality, as well as higher healthcare costs. To address this issue, the market is focused on developing new antibiotics, diagnostics, and vaccines, as well as strategies to reduce the spread of drug-resistant bacteria. Additionally, the market is focused on improving the stewardship of existing antibiotics, as well as developing new strategies to reduce the emergence of drug-resistant bacteria.
Some companies in the AMR market include Merck & Co., Pfizer, GlaxoSmithKline, Sanofi, Johnson & Johnson, Novartis, and AstraZeneca. Show Less Read more